Between Reality and Representation: Exclusion of Subpopulations in Anti‐Amyloid Therapy

Patients receiving anti-amyloid therapy are largely biased towards White race and non-hispanic individuals. Individuals with dementia comprised the majority of individuals receiving anti-amyloid therapy. These data reveal significant disparities in access to anti-amyloid therapy. The low inclusion of Black and Hispanic populations compromises the generalizability of clinical outcomes and reflects broader systemic inequities. Initiating therapy predominantly at the dementia stage suggests missed opportunities for early diagnosis and may attenuate treatment benefits. Addressing these disparities through inclusive trial design, public health policy, and cost reduction is essential to ensure equitable access and maximize the impact of disease-modifying therapies in AD.